Side-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study

Simple item page
dc.contributor.authorOnyango, Jagire
dc.contributor.authorMukunya, David
dc.contributor.authorNapyo, Agnes
dc.contributor.authorNantale, Ritah
dc.contributor.authorMakoko, Brian T
dc.contributor.authorMatovu, Joseph K B
dc.contributor.authorWanume, Benon
dc.contributor.authorOkia, David
dc.contributor.authorOkello, Francis
dc.contributor.authorOkware, Sam
dc.contributor.authorOlupot-Olupot, Peter
dc.contributor.authorLubaale, Yovani
dc.date.accessioned2023-01-24T14:05:53Z
dc.date.available2023-01-24T14:05:53Z
dc.date.issued2022-11
dc.description.abstractAbstract: Effective, safe and proven vaccines would be the most effective strategy against the COVID-19 pandemic but have faced rollout challenges partly due to fear of potential side-effects. We assessed the prevalence, profiles, and predictors of Oxford/AstraZeneca vaccine side-effects in Tororo district of Eastern Uganda. We conducted telephone interviews with 2204 participants between October 2021 and January 2022. Multivariable logistic regression was conducted to assess factors associated with Oxford/AstraZeneca vaccine side-effects using Stata version 15.0. A total of 603/2204 (27.4%) of the participants experienced one or more side-effects (local, systemic, allergic, and other side-effects). Of these, 253/603 (42.0%) experienced local side-effects, 449/603 (74.5%) experienced systemic side-effects, 11/603 (1.8%) experienced allergic reactions, and 166/603 (27.5%) experienced other side-effects. Ten participants declined to receive the second dose because of side-effects they had experienced after the first dose. Previous infection with COVID-19 (adjusted odds ratio (AOR): 4.3, 95% confidence interval (95% CI): 2.7–7.0), being female (AOR: 1.3, 95% CI: 1.1–1.6) and being a security officer (AOR: 0.4, 95% CI: 0.2–0.6) were associated with side-effects to the Oxford/AstraZeneca vaccine. We recommend campaigns to disseminate correct information about potential side-effects of the Oxford/AstraZeneca vaccine and strengthen surveillance for adverse events following vaccination.en_US
dc.description.sponsorshipThis research received no external funding. The Norwegian Research School of Global Health funded the article processing charges for this manuscript. D.M. is an alumnus of the schoolen_US
dc.identifier.citationOnyango, Jagire, David Mukunya, Agnes Napyo, et al. 'Side-Effects Following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study', International Journal of Environmental Research and Public Health, vol. 19/no. 22, (2022), pp. 15303.en_US
dc.identifier.issn1661-7827 (Print)
dc.identifier.issn1660-4601 (Online)
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/7161
dc.language.isoenen_US
dc.publisherMDPI AGen_US
dc.subjectside-effects, COVID-19, Oxford/AstraZeneca vaccine, Ugandaen_US
dc.titleSide-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijerph-19-15303.pdf
Size:
799.94 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences